Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model

Prostate

Volumn 67, Issue 7, 2007, Pages 685-691

  Hsieh, Chia Ling ^a   Xie, Zhihui ^a   Yu, Jie ^a   Martin, W David ^a   Datta, Milton W ^a   Wu, Guang Jer ^a   Chung, Leland W K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bigenic transgenic mouse; Bioluminescence imaging; Prostate cancer bone metastasis; Supra prostate specific antigen (sPSA) promoter; TRAMP model

Indexed keywords

ANDROGEN RECEPTOR; LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE TUMOR; CANCER GROWTH; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MARKER; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; METASTASIS; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE DISTRIBUTION;

ANIMALS; ANTIGENS, VIRAL, TUMOR; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; LUCIFERASES; LUMINESCENT PROTEINS; LYMPHATIC METASTASIS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25;

EID: 34248160630     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20510     Document Type: Article

References (19)

1. Grippo PJ, Sandgren EP. Modeling pancreatic cancer in animals to address specific hypotheses. Methods Mol Med 2005;103:217-243.
2. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004;16(2):143-150.
3. Winter SF, Cooper AB, Greenberg NM. Models of metastatic prostate cancer: A transgenic perspective. Prostate Cancer Prostatic Dis 2003;6(3):204-211.
4. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56(18):4096-4102.
5. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92(8):3439-3443.
6. Sato A, Klaunberg B, Tolwani R. In vivo bioluminescence imaging. Comp Med 2004;54(6):631-634.
7. Lyons SK, Meuwissen R, Krimpenfort P, Berns A. The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res 2003;63(21):7042-7046.
8. Vooijs M, Jonkers J, Lyons S, Berns A. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res 2002;62(6):1862-1867.
9. Hsieh CL, Xie Z, Liu ZY, Green JE, Martin WD, Datta MW, Yeung F, Pan D, Chung LW. A luciferase transgenic mouse model: Visualization of prostate development and its androgen responsiveness in live animals. J Mol Endocrinol 2005;35(2):293-304.
10. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 2000;275(52):40846-40855.
11. Arnold W. Immunohistochemical investigation of the human inner ear. Limitations and prospects. Acta Otolaryngol 1988;105(5-6):392-397.
12. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57(21):4687-4691.
13. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55(3):219-237.
14. Sung SY, Chung LW. Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002;70(9-10):506-521.
15. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8(2):230-239.
16. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999;6(4):503-519.
17. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001;61(5):2239-2249.
18. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci USA 1998;95(26):15382-15387.
19. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64(6):2270-2305.